Vertex Gets CHMP Recommendation For Orkambi Label Expansion
Zacks Investment Research | Nov 13, 2017 02:20AM ET
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) announced that the Committee for Medicinal Products for Human Use ("CHMP") has recommended approval of a label expansion for Orkambi in Europe. The company is seeking extension of its marketing authorization for Orkambi to include use in children with cystic fibrosis ("CF") who are aged between 6 and 11 years and have two copies of the F508del mutation.
We note that the European Commission generally follows the recommendation of the CHMP but is not bound by it. A decision is typically expected within three months of recommendation.
We remind investors that Orkambi is currently approved in the EU for the treatment of CF in patients aged 12 years and above who have two copies of the F508del mutation in their CF transmembrane conductance regulator ("CFTR") gene.
Vertex’s stock has outperformed the industry so far this year. Shares are up 101.9% compared with the industry’s gain of 2.3% in the period.
The company believes that the label expansion will increase the eligible patient population by 3400 in Europe. The drug is already approved in the United States for this indication.
Orkambi generated net sales of $955.5 million in the first nine months of 2017, growing over 35% from the year-ago period. The potential label expansion will further boost the drug’s sales.
Meanwhile, the company has completed part 2 of a phase III study evaluating Orkambi in CF patients of two to five years of age who have two copies of the F508del mutation in their CFTR gene. Last month the company announced that the study met its primary endpoint of safety. Vertex expects to file applications for expanding Orkambi’s label in this patient population to the regulatory authorities in the United States and Europe in the first quarter of 2018.
CF, a rare, life-threatening disease, is estimated to affect approximately 75,000 people in the United States, Europe and Australia. Vertex currently has another CF drug, Kalydeco, in its portfolio. The company generated CF product revenues of more than $1.5 billion, including sales of Kalydeco and Orkambi, in the first nine months of 2017.
Moreover, to boost its CF portfolio and curb competition Vertex bought Concert Pharmaceuticals, Inc.’s (NASDAQ:CNCE) CF candidate, CTP-656, in July 2017.
The CF market has been attracting lot of interest with several companies developing their candidates as potential therapy for patients.
Get The News You Want
Vertex Pharmaceuticals Incorporated Price
Vertex Pharmaceuticals Incorporated Quote
Zacks Rank & Stocks to Consider
Vertex carries a Zacks Rank #3 (Hold).
A couple of better-ranked health care stocks include Ophthotech Corporation (NASDAQ:OPHT) and Ligand Pharmaceuticals Inc. (NASDAQ:LGND) . While Ophthotech sports a Zacks Rank #1 (Strong Buy), Ligand carries a Zacks Rank #2 (Buy). You can see .
Ophthotech’s earnings per share estimates have moved up from 81 cents to $2.31 for 2017 over the last 30 days. The company delivered a positive earnings surprise in all the trailing four quarters, with an average beat of 14.23%.
Ligand’s earnings per share estimates have moved up from $3.68 to $3.70 for 2018 over the last 60 days. The company pulled off a positive earnings surprise in two of the trailing four quarters, with an average beat of 8.22%. The share price of the company has increased 37.7% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.